website-header.png

Comprehensive profiling of skin and blood of alopecia areata patients enrolled in an open label trial of tofacitinib

Year: 
2015 to 2017
Ali Jabbari, MD, PhD, Principal Investigator
Columbia University

Pilot & Feasibility Grant Opportunities

Significance

Biomarkers are important in evaluating how well treatments in clinical trials work, and this work could allow researchers to determine which new treatments are going to work the best for alopecia areata. If the study realizes its goal of finding a predictor of outcome for alopecia areata patients considering treatment with tofacitinib, it will be of great utility to physicians.

Purpose

To identify biomarkers in the skin and blood of alopecia areata patients enrolled in tofacitinib clinical trial that would allow us to precisely and accurately track the disease.